Press

COMPASS Pathways granted fifth US patent for crystalline psilocybin

Nov 23 • 2 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office (USPTO). This is COMPASS’s 10th patent overall, with five now granted in the US, two in the UK, one in Germany and two in Hong…

Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results and Provides Business Update

Nov 22 • 8 min read

Field Trip Health Ltd. (NASDAQ: FTRP), a leader in the development and delivery of psychedelic therapies, reported its second fiscal quarter 2022 results for the three months ended September 30, 2021 and provided a business update. All results are reported under International Financial Reporting Standards (“IFRS“) and in Canadian dollars, unless otherwise specified. Key Highlights…

Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments

Nov 19 • 2 min read

Wesana Health Holdings Inc. (CSE: WESA), a data-driven life sciences company, announced today that the Company’s Wesana Clinics business segment has surpassed 4,000 administered ketamine treatments for major depressive disorder, anxiety, PTSD, and addiction since inception. “This is a significant achievement for Wesana Clinics. There is an urgent need for innovative and effective treatments to…

Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders

Nov 19 • 2 min read

Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has received correspondence from the U.S. Food and Drug Administration related to the Company’s Investigational New Drug application for a clinical study in overeating disorders. The FDA has requested certain changes to the protocol…

Filament Health Announces Co-Development and Exclusive Licensing Agreement with Entheotech Bioscience

Nov 18 • 3 min read

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it has entered into a co-development and exclusive licensing agreement with EntheoTech Bioscience Inc., a bioscience company focused on the research and development of formulas and protocols to support opioid tapering and treat chronic pain, depression and…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435